Fierce Pharma

MARCH 7, 2024

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

Sales 193

Sales 193

pharmaphorum

JANUARY 10, 2023

Its ability to accelerate R&D programmes, energise real-time clinical decision making and sharpen connections between pharma organisations and clients is clear and they can combine to positively impact patient outcomes. Pharma is a highly regulated industry and that is often why it is slow to adopt new technologies,” says Kazuki.

Marketing 98

Marketing Pharma Sales Healthcare 98

pharmaphorum

JUNE 27, 2022

per share for Cambridge, Massachusetts-based Epizyme – valuing the US company at around $247 million – and is also promising a further contingent value right (CVR) payment of up to $1 per share if Tazverik (tazemetostat) achieves certain development and sales targets. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30

Biopharma 111

Biopharma Sales Prescription FDA 111

Pharmaceutical Commerce

FEBRUARY 21, 2025

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on other concepts that are powering the companys 2025 Supply Chain Trends Report, and how they could possibly change in 2026.

Electronics 52

Electronics Sales Pharma 52

pharmaphorum

AUGUST 5, 2022

Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world’s second-largest pharma market.

Side effects 104

Side effects Marketing Pharma Medicine 104

PM360

SEPTEMBER 21, 2023

Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

JANUARY 16, 2023

Pharma may have to navigate a difficult path through relatively slow-to-fall inflation in regions outside the US. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. The entire pharma industry will be affected by the fallout. Free Report.

Pharma 64

Pharma Pharmaceutical Manufacturing Marketing 64

PM360

APRIL 7, 2023

Dan Renick The IRA presents market access teams with a unique opportunity to make recommendations to CMS regarding the evidence and methodology that will be applied in evaluating drugs for upcoming Medicare negotiations that will lead to price adjustments in 2026. Given the volume of 340B sales (13% of total U.S.

Manufacturing 97

Manufacturing Insurance Marketing Government 97

Pharmaceutical Technology

APRIL 10, 2023

India-based pharmaceutical company Cipla has entered into a perpetual licence agreement with Swiss drugmaker Novartis Pharma for the diabetes drug Galvus and its combination brands. Under the deal, Cipla will be responsible for the manufacturing and marketing of Galvus and its combination brands from 1 January 2026.

Manufacturing 52

Manufacturing Medicine Sales Pharma 52

Pharmaceutical Technology

JANUARY 16, 2023

Pharma may have to navigate a difficult path through relatively slow-to-fall inflation in regions outside the US. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. The entire pharma industry will be affected by the fallout. Free Report.

Pharma 52

Pharma Pharmaceutical Manufacturing Marketing 52

pharmaphorum

JANUARY 18, 2023

German pharma group Bayer has made another play in the digital medical imaging category, buying Blackford Analysis and its artificial intelligence-based platform for radiological assessments. The business generated sales of €1.8 billion (approximately $1.9 billion) in 2021, around 10% of the group’s total healthcare revenues.

Medical 59

Medical Pharma Media Sales 59

European Pharmaceutical Review

AUGUST 22, 2024

Based on their rising popularity to treat type 2 diabetes and obesity, GlobalData has predicted that sales of glucagon-like peptide-1 receptor (GLP-1R) drugs will increase fourfold to an estimated $142 billion by 2030. Eli Lilly shared that production of the medicines will commence at the Lebanon site towards the end of 2026.

Medicine 59

Medicine Marketing Manufacturing Sales 59

PM360

APRIL 7, 2023

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

pharmaphorum

NOVEMBER 25, 2022

German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan’s Kyowa Kirin, which are currently sold by affiliate companies across Europe.

Medicine 52

Medicine Marketing Pharma Management 52

pharmaphorum

SEPTEMBER 23, 2022

Chances of FDA approval for Spectrum Pharma’s lung cancer candidate poziotinib and Oncopeptides’ Pepaxto for multiple myeloma have taken a dive, after the regulator’s expert advisors voted that the drugs were not ready to reach the market.

FDA 52

FDA Patients Marketing Recruitment 52

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

SEPTEMBER 30, 2022

7,326,708) was challenged by Mylan Pharma, now Viatris, before the US Patent and Trademark Office (USPTO), which ruled in Merck’s favour last year. That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No. The US patent (No. billion in the first half of 2022.

Marketing 59

Marketing Sales Competition FDA 59

PM360

SEPTEMBER 21, 2023

Our solutions enable pharma manufacturers to engage with providers and patients so they can start and stay on the right medication and improve their health outcomes. We often say that our platform enables pharma brands across all specialties to “reach the audience they want at the scale they need,” across the entire health journey.

Prescription 52

Prescription Medical Patients Distribution 52

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Furthermore, the 2020 post-pandemic launches, for which we now have up to 21 months of sales, show continued average underperformance.

Doctors 59

Doctors Medicine Marketing Sales 59

pharmaphorum

NOVEMBER 6, 2022

The antibody-based drug has been cleared by the European Commission with a broad label, covering both full-term and pre-term babies and those with a range of health conditions that could make the vulnerable to RSV, said the two pharma groups in a statement. It is the first approval for Beyfortus (nirsevimab) by any regulatory authority.

Marketing 65

Marketing Sales Manufacturing Pharma 65

Healthcare Success

JANUARY 27, 2025

Prioritize Education Over Sales Older adults and seniors prefer unbiased education over high-pressure sales tactics to make informed decisions. We work with Pharma or Medicare or whatever. Leverage Multichannel Marketing Create a consistent, unified message across various channels (e.g., They're all different. It's changing.

Marketing 65

Marketing Education Media Leads 65

PM360

JANUARY 24, 2025

The first Trump administration issued an Executive Order in 2020 to pass drug rebates to patients at the point of sale, but the Biden Administration did not implement it. As such, when CMS releases its report this March about the 10 drugs negotiated for 2026, it will hopefully shed light on the value metrics CMS utilized to set prices.

Food and Drug Administration 52

Food and Drug Administration Manufacturing Insurance Pharmaceutical 52